Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback